When My Doctor Does Not Agree With Weight Loss Medication

How to find the real point of disagreement when two clinicians you trust give you opposite advice about GLP-1 treatment.

If my doctor does not agree with weight loss medication and another clinician does, the disagreement is rarely about the whole drug class. Something specific is driving it: a risk in your history, a dose, an interaction, or a piece of your chart one of them has never seen. Find that one thing, then put both clinicians in front of it.

Why do two good doctors disagree about the same patient?

They are answering different questions. Say your primary care physician has known you nine years. She holds the whole chart: kidney function, an old gallbladder problem, the two rounds of weight you lost and regained. One more prescription has to earn its place against all of it.

A clinician who works in obesity medicine all day answers a narrower question. Does this patient meet criteria for pharmacologic treatment of a chronic metabolic condition, and if so, how do we start and monitor it safely. Narrow can still be careful.

I have seen many of these standoffs turn out to be an information gap dressed as a clinical fight. The primary doctor holds labs the weight clinic never received. The weight clinic wrote a monitoring plan nobody sent over. Two careful people, half a file each.

How do I find the actual point of disagreement?

Ask in one sentence. "What specifically about my case makes you hesitant?" Short, unaccusing, and it asks for a reason where most patients ask for permission.

Some answers close the door, and they should. A personal or family history of medullary thyroid carcinoma or MEN2 is a contraindication to this class of medication, and no documentation changes that. Pregnancy, or planning one soon, rules these drugs out for now. If that is her hesitation, she is right, and the conversation turns to what else can help your metabolic health.

Other answers are questions with documents behind them:

• Medication management. Insulin or a sulfonylurea needing dose reductions as intake falls. A drug whose absorption may shift as gastric emptying slows.
• Sequencing. She wants thyroid function checked, untreated sleep apnea addressed, or a disordered eating pattern assessed first.
• Illness that needs a real decision. Prior pancreatitis, active gallbladder disease, significant gastroparesis. Records help, a specialist helps more, and sometimes the answer stays no.
• The source of the medication. Compounded products raise this one, and it deserves specifics.
• Clinical philosophy. A view that medication belongs later, after a longer trial of other measures.

The first four move with records and a phone call. The last is a difference in philosophy, and here is mine: an open-ended "try harder first," with no time limit and no endpoint, is the weakest version of it. Obesity has a biological floor that pulls weight back up, and asking a patient who has made several serious attempts to make one more, with nothing to measure, asks her to keep paying for a result her physiology takes back. A time-limited trial with a written checkpoint is defensible.

What should I bring so the conversation is useful?

Bring paper. Four things, specifically, before a physician puts her name on a plan:

• Your weight history: what you tried, and what happened the year after you stopped.
• Labs from the last six to twelve months: A1c, fasting glucose, lipids, thyroid function, liver enzymes.
• Every medication and supplement, including the occasional ones.
• The exact plan: which medication, starting dose, titration schedule, who monitors what and how often, and what result would stop it.

That last line matters more than patients realize. A cautious physician is often arguing about accountability, not pharmacology; she is being asked to co-sign something she cannot see.

What if the disagreement is about compounded medication?

Here is a composite, details changed. A patient forwards me a message from her primary doctor: "I am not comfortable with this. I do not know what is in it." That is not hostility. That is a physician asked to put her license behind a product she cannot trace.

Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not identical to the brand versions. They are prepared by state-licensed compounding pharmacies operating under section 503A after patient-specific and location-specific verification. Fulfillment happens only when a prescription is approved and the pharmacy can fulfill it for the patient's location, with packaging and shipping confirmed before fulfillment. Our clinic is in Costa Mesa, California; because care is delivered by telehealth, prescribing and shipping depend on where the patient is and are confirmed before any treatment decision.

So answer with specifics: the prescribing clinician's name and license, the pharmacy, the drug, the concentration, the titration schedule, the monitoring plan. In our practice those are available on request. The initial physician review is $119 one time, which covers the doctor review and the prescription if approved, and medication is billed separately.

Ozempic and Wegovy are products of Novo Nordisk. Mounjaro and Zepbound are products of Eli Lilly. Our clinic is not affiliated with or endorsed by either company.

What if one doctor talks about results and the other about risk?

A benefit number and a risk number do not sit on the same scale, which is why these two talk past each other. In the STEP program published in the New England Journal of Medicine in 2021, semaglutide 2.4 mg averaged 14.9 percent weight loss over 68 weeks alongside lifestyle changes, and about one in three participants reached 20 percent or more. In SURMOUNT-1, published in the same journal in 2022, tirzepatide at the highest studied dose averaged about 20.9 percent over 72 weeks. Those studies tested the FDA-approved brand products; compounded semaglutide and compounded tirzepatide are not FDA-approved and are not identical to the brand versions, so the figures do not transfer. They are trial averages under trial conditions, no clinic can promise them, and results vary by individual.

Now the other column of the ledger. Nausea, vomiting, diarrhea and constipation are common, particularly while the dose climbs. Gallbladder disease, including stones and inflammation, occurs. Pancreatitis is uncommon and serious. Dehydration from unmanaged vomiting can injure the kidneys. Hypoglycemia is a live concern for patients on insulin or a sulfonylurea.

And here is what we still cannot do: predict who will lose a quarter of her body weight and who will lose four pounds and stall. No blood test sorts them. We start, and then we find out, which is uncomfortable to say to a patient who came in wanting certainty. A doctor who wants a defined checkpoint first is asking a sound question.

Who decides if the two of them still disagree?

You do. Informed consent puts the decision with the person whose body it is, and two licensed clinicians reaching different recommendations does not change that.

Ask the hesitant one: "What would need to be true for you to be comfortable with this?" The answer is usually something you can go and get. A lab value. A gastroenterology consult. Then pick among three outcomes: start treatment and route monitoring back to your primary doctor, agree on a defined trial with a scheduled reassessment, or accept the wait in writing, with the condition that would reopen it.

Going quiet is the option with no upside. Starting a GLP-1 medication without telling the physician who manages your insulin or your blood pressure carries the highest risk of a preventable interaction, because the person adjusting those doses is working from a medication list that is wrong. Patients go quiet because they are tired of feeling judged. I understand it. Tell her anyway.

Sometimes it does not resolve. Two clinicians read the same chart and land in different places, and you decide with incomplete information, which describes most of medicine. Write down the date, what each of them said, and what you chose. Six months from now, one of you will want to read it.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.